By If you’ve been diagnosed with depression – or are trying to understand treatment options for someone you care about – the landscape can feel overwhelming. Medications, therapies, lifestyle approaches, newer treatments, alternative options. Conflicting information everywhere. And underneath it all, the very real question of whether anything will actually help.
The honest answer is that depression is one of the most treatable conditions in medicine. Approximately 80% of people with major depression who receive appropriate, evidence-based treatment experience significant improvement. The challenge is finding the right combination for the individual – because what works varies considerably between people – and maintaining treatment long enough for it to work.
This article covers every major evidence-based treatment approach, what the research actually shows about each, and how to think about choosing between them.
The Foundation: Why Treatment Takes Time
Before covering specific treatments, one point is worth establishing: depression treatment requires patience in a way that’s genuinely difficult for the depressed brain, which has altered time perception, hopelessness, and reduced motivation.
Antidepressants typically take 4-6 weeks to produce meaningful clinical benefit – some people see improvements earlier, but a fair trial requires at least 4-6 weeks at an adequate dose. Psychotherapy typically requires 8-16 sessions before significant symptom change. Even ketamine, which works faster than anything else, requires ongoing treatment to maintain its effects.
The single biggest reason depression treatment fails isn’t that the treatment doesn’t work – it’s that people stop before it has a chance to work. Understanding this in advance makes it possible to make a more informed commitment.
Psychotherapy
Psychotherapy is not just “talking about your feelings.” Evidence-based psychotherapy involves structured, skills-based approaches that have been tested in hundreds of randomized controlled trials and shown to produce measurable, lasting changes in depression symptoms.
Cognitive Behavioral Therapy (CBT)
CBT is the most extensively studied psychological treatment for depression, with evidence from over 500 randomized controlled trials. It’s based on the observation that depression is maintained by specific patterns of distorted thinking (cognitive distortions) and avoidant behavior that can be identified and changed.
What it does: CBT targets the negative automatic thoughts that are pervasive in depression (“I’m worthless,” “nothing will ever improve,” “I’m a burden”), examines the evidence for and against them, and develops more realistic and balanced thinking patterns. It also addresses behavioral patterns – particularly the avoidance and withdrawal that maintain and deepen depression – through behavioral activation (deliberately engaging in activities despite not feeling like it).
How effective is it? Meta-analyses consistently show CBT is as effective as antidepressants for mild-to-moderate depression, and combination treatment (CBT plus medication) outperforms either alone for moderate-to-severe depression. A critical advantage: CBT’s benefits tend to be more durable than medication alone – lower relapse rates after treatment ends because patients have developed skills they continue to use.
Format: Typically 12-20 sessions, though brief CBT (6-8 sessions) has evidence for mild-to-moderate depression. Increasingly available via digital platforms (computerized CBT) with reasonable evidence for effectiveness.
Behavioral Activation (BA)
Behavioral activation focuses specifically on the behavioral component of depression – breaking the cycle of withdrawal and inactivity by scheduling and engaging in meaningful activities, even before mood improves. It emerged from research showing that the behavioral component of CBT was as effective as the full package.
BA is simpler to deliver than full CBT and can be implemented in fewer sessions, making it a viable approach in settings with limited specialist availability.
Interpersonal Therapy (IPT)
IPT focuses on the role of interpersonal relationships in depression – specifically, how life events involving grief, role transitions, role disputes, and interpersonal deficits connect to depressive episodes. It’s time-limited (typically 12-16 sessions) and focuses on current interpersonal functioning rather than past experiences.
IPT has particularly strong evidence for postpartum depression and for depression occurring in the context of major life transitions or relationship difficulties.
Mindfulness-Based Cognitive Therapy (MBCT)
MBCT combines CBT elements with mindfulness meditation training. It’s specifically designed and evidenced for relapse prevention in people who have had three or more depressive episodes – the population at very high recurrence risk. It teaches people to recognize early warning signs of relapse and respond to them differently, without being swept back into depression.
Evidence shows MBCT reduces relapse rates in high-risk patients by approximately 40-50% compared to usual care alone.
Problem-Solving Therapy (PST)
A structured, brief (6-8 sessions) approach focused on developing concrete problem-solving skills for the life difficulties that contribute to depression. Particularly useful when depression is significantly connected to ongoing life stressors and problems.
Access to Psychotherapy
A practical reality: access to evidence-based psychotherapy, particularly CBT, is limited by availability, cost, and waiting lists in many parts of the US. Solutions:
- University training clinics often offer reduced-fee therapy with supervised trainees
- Online CBT platforms (some with strong evidence) include Shim, Woebot, MoodKit
- Guided self-help (CBT workbooks with minimal clinician contact) has reasonable evidence for mild-to-moderate depression
- Some employers provide Employee Assistance Programs (EAPs) with free short-term counseling
- Open Path Collective offers reduced-fee therapy matching
Antidepressant Medications
Medication is the most common treatment for depression in the US – more people receive antidepressants than psychotherapy, partly due to access and partly due to the way healthcare is organized around prescriptions rather than therapy.
SSRIs – The First Line
Selective serotonin reuptake inhibitors are the most prescribed antidepressants globally. They work by blocking the reuptake of serotonin at the synapse – increasing serotonin availability. Their mechanism is more complex than the simple “chemical imbalance” story suggests, but the clinical efficacy is well-established.
Common SSRIs: fluoxetine (Prozac), sertraline (Zoloft), escitalopram (Lexapro), citalopram (Celexa), paroxetine (Paxil), fluvoxamine (Luvox)
Efficacy: A landmark 2018 meta-analysis in The Lancet (Cipriani et al.) covering 522 trials and 116,000+ patients confirmed that all commonly used antidepressants are more effective than placebo, with effect sizes ranging from modest to moderate. Response rates (meaningful improvement) are approximately 50-60% with the first antidepressant tried.
What to expect: Initial effects (improved sleep, reduced agitation) sometimes appear in the first 1-2 weeks. Full antidepressant effects typically take 4-6 weeks. Trials should be at least 6-8 weeks at an adequate dose before concluding non-response.
Common side effects: Nausea (often transient), insomnia or sedation (varies by drug), sexual dysfunction (decreased libido, delayed orgasm – affects 30-40% of patients and is one of the most common reasons for discontinuation), headache, weight changes with long-term use.
Discontinuation syndrome: SSRIs are not physically addictive, but stopping them abruptly – particularly paroxetine and venlafaxine – can produce discontinuation symptoms (flu-like symptoms, dizziness, “brain zaps,” irritability). Always taper under medical guidance.
SNRIs
Serotonin-norepinephrine reuptake inhibitors (venlafaxine/Effexor, duloxetine/Cymbalta, desvenlafaxine/Pristiq) block reuptake of both serotonin and norepinephrine. Comparable efficacy to SSRIs for depression; the norepinephrine effect adds benefit for anxiety symptoms and physical pain (duloxetine is FDA-approved for several pain conditions).
Atypical Antidepressants
Several antidepressants don’t fit neatly into SSRI/SNRI categories:
Bupropion (Wellbutrin): Dopamine and norepinephrine reuptake inhibitor. More activating than SSRIs – useful for fatigue, low motivation, and hypersomnia. Lower rates of sexual dysfunction. Contraindicated in seizure disorders and anorexia (lowers seizure threshold). FDA-approved for both depression and smoking cessation.
Mirtazapine (Remeron): Blocks alpha-2 receptors and certain serotonin receptors. Produces sedation and appetite stimulation – beneficial when insomnia and appetite loss are significant, challenging when weight gain or sedation are concerns.
Trazodone: Low doses are used as a sleep aid; higher doses have antidepressant effects. Less commonly used as a primary antidepressant today.
Tricyclic Antidepressants (TCAs)
Older antidepressants (amitriptyline, nortriptyline, imipramine) effective for depression but with broader side effect profiles (anticholinergic effects, cardiac effects, dangerous in overdose) limiting their use as first-line agents. Still used in specific situations, including pain syndromes.
MAOIs
Monoamine oxidase inhibitors (phenelzine, tranylcypromine) are effective – particularly for atypical depression – but require strict dietary restrictions (avoiding tyramine-containing foods) and have many drug interactions. Rarely used today except for treatment-resistant cases.
Choosing Between Medications
No antidepressant has been shown definitively superior for most patients. Choice is guided by:
- Side effect profile (a patient with insomnia and weight loss benefits from mirtazapine; one with hypersomnia and fatigue benefits from bupropion)
- Prior response history (if a specific antidepressant worked before, try it again)
- Family response history (genetic factors influence response)
- Specific comorbidities (pain → duloxetine; smoking cessation → bupropion; anxiety → SSRI/SNRI)
- Drug interactions and other medications
If the first antidepressant doesn’t work adequately, the approach is to switch to a different medication or augment with another agent – not to give up on medication. The STAR*D trial, which followed thousands of depressed patients through multiple treatment steps, showed that after four sequential treatment trials, approximately 67% achieved remission.
Combination Treatment: Medication Plus Therapy
The most robust evidence consistently shows that combining antidepressant medication with psychotherapy (particularly CBT) outperforms either alone for moderate-to-severe depression:
- Greater likelihood of initial response
- Greater likelihood of full remission (not just improvement)
- Lower relapse rates after treatment ends
- More durable outcomes
If resources allow, combination treatment should be the goal for moderate-to-severe depression. Medication can provide sufficient symptom relief to make engagement with therapy possible when depression has been too severe to participate.
Exercise
Exercise is among the most evidence-backed non-pharmacological interventions for depression. A 2023 British Medical Journal meta-analysis covering 97 systematic reviews and over 128,000 participants found exercise was highly effective for depression – comparable to antidepressants for mild-to-moderate depression.
The mechanisms: Exercise increases BDNF (supporting neuroplasticity), increases serotonin and dopamine, reduces inflammatory markers, regulates cortisol, and improves sleep – addressing multiple biological pathways relevant to depression simultaneously.
What type and how much: Both aerobic exercise (walking, running, cycling, swimming) and resistance training have evidence. Vigorous-intensity exercise shows the largest effects in some analyses. The dose that appears effective: at least 3 sessions per week, 30-45 minutes each, at moderate-to-vigorous intensity.
The practical challenge: The very nature of depression – fatigue, anhedonia, reduced motivation – makes starting exercise enormously difficult. This is not a moral failing. Starting small (a 10-minute walk daily) and building gradually, with support and accountability, is more realistic than immediately targeting full guidelines.
Exercise works best as an adjunct to other treatments, not a standalone treatment for moderate-to-severe depression.
Light Therapy
Light therapy is the first-line treatment for seasonal affective disorder and has evidence for non-seasonal MDD as well.
How it works: A 10,000-lux white light box (UV-filtered) used for 20-30 minutes in the morning mimics the circadian and melatonin-regulating effects of morning sunlight.
Evidence: For SAD, light therapy is as effective as antidepressants. For non-seasonal MDD, it augments antidepressant treatment. Combining light therapy with antidepressants outperforms either alone.
Practical notes: Must be used consistently throughout the vulnerable season. Eyes must be open but don’t look directly at the light. Effects begin within days to 1-2 weeks. Morning timing is essential – evening light exposure can worsen sleep.
Newer and Advanced Treatments
Ketamine and Esketamine (Spravato)
Ketamine produces rapid antidepressant effects – often within hours – through NMDA receptor antagonism and downstream effects on glutamate signaling, BDNF, and AMPA receptors. The FDA approved esketamine (Spravato) nasal spray in 2019 for treatment-resistant depression and for major depression with acute suicidal ideation.
The rapid onset makes ketamine particularly valuable in severe depression with suicide risk and for people who have failed multiple medication trials. The primary limitation is that the effects require ongoing infusions to maintain – the antidepressant effect doesn’t persist after treatment stops without continued dosing.
Available through specialized ketamine clinics and psychiatric practices. Not yet widely covered by insurance.
Transcranial Magnetic Stimulation (TMS)
FDA-cleared for treatment-resistant depression. Non-invasive magnetic stimulation of the left dorsolateral prefrontal cortex (reduced activity in this region is characteristic of depression) – 20-40 minute sessions, typically 5 days per week for 4-6 weeks.
Effective for approximately 50-60% of treatment-resistant patients; about one-third achieve remission. No significant systemic side effects (no sexual dysfunction, weight change, or cognitive impairment). Requires daily sessions for weeks, limiting practical access.
Electroconvulsive Therapy (ECT)
Despite stigma, ECT is the most effective treatment for severe treatment-resistant depression – producing remission in 60-80% of patients who have failed multiple other treatments. Modern ECT uses general anesthesia, muscle relaxants, and precisely controlled electrical stimulation to produce a brief therapeutic seizure.
ECT is used when: multiple adequate medication trials have failed, there is severe suicide risk requiring rapid response, severe psychotic depression, catatonia, or when antidepressants are medically contraindicated. The primary side effect is transient memory disruption (particularly around the time of treatment) that typically resolves after the treatment course.
What Doesn’t Work as Sole Treatment
Willpower and positive thinking: These are not treatments. They are responses to the mistaken view that depression is a choice or attitude problem. Useful coping strategies exist, but they augment rather than replace evidence-based treatment.
Alcohol and substance use: Among the most counterproductive self-medication approaches. Alcohol reliably worsens depression over time, disrupts sleep, interacts badly with antidepressants, and increases suicide risk.
Waiting it out: Untreated depression does often eventually remit – but over months during which suffering, functional impairment, and suicide risk are all elevated. Waiting without treatment is rarely the optimal approach for a condition with good treatment options.
Finding the Right Treatment: Practical Steps
- See a doctor or mental health professional for assessment. Self-diagnosis and self-treatment (outside of lifestyle measures) are not sufficient for moderate-to-severe depression.
- Be honest about severity. Treatment intensity should match severity – mild depression may start with therapy; moderate-to-severe depression typically warrants medication plus therapy.
- Give each treatment a fair trial. Four to six weeks at an adequate dose for medication; 8-16 sessions for psychotherapy. Stopping early is the most common reason treatment fails.
- Address sleep, alcohol, and exercise alongside formal treatment. These amplify or undermine treatment outcomes.
- If the first treatment doesn’t work, try another – not give up. Treatment-resistant depression is common, and multiple options exist.
- Discuss maintenance treatment. After a first episode, most guidelines recommend continuing antidepressant treatment for 6-12 months after remission. After two or more episodes, longer-term maintenance significantly reduces recurrence.
Frequently Asked Questions
How do I choose between therapy and medication? For mild depression, either works as a starting point. For moderate-to-severe depression, combination treatment is most effective. Practical factors: therapy requires time commitment and access (and works more slowly initially); medication requires medical supervision and tolerance of side effects. People with prior good response to medication, time constraints, or difficulty engaging with therapy may start with medication; those who prefer to avoid medication, with strong CBT access, or with mild symptoms may start with therapy.
Will I need antidepressants forever? Not necessarily. Many people have a finite number of depressive episodes and can taper off medication after achieving sustained remission. However, for those with recurrent depression (multiple episodes), long-term maintenance treatment significantly reduces the risk of relapse. The decision depends on episode history, severity, and individual preference – made with a prescribing doctor.
Do antidepressants work for everyone? No – approximately 50-60% of people respond to the first antidepressant tried. With sequential trials (switching or augmenting), response rates rise to approximately 67% after multiple treatment steps (STAR*D trial). Some people don’t respond to standard antidepressants and require alternative approaches.
Is there anything I can do right now, today? Yes: Get morning light exposure (go outside within an hour of waking). Move your body, even briefly. Reach out to one person you trust. Avoid or reduce alcohol. Maintain a consistent wake time. These won’t treat depression alone, but they reduce the biological factors that maintain it and make formal treatment more effective.
What if I can’t afford therapy or medication? Community mental health centers (FQHCs) provide sliding-scale mental health care. Federally Qualified Health Centers provide integrated primary care including mental health services on a sliding scale. Generic antidepressants (fluoxetine, sertraline, bupropion) are available for very low cost with GoodRx or similar programs. Open Path Collective offers reduced-fee therapy. NAMI’s helpline (1-800-950-6264) provides resource navigation.
If You’re Struggling Right Now
988 Suicide and Crisis Lifeline: Call or text 988 (US) – 24/7, free and confidential. Crisis Text Line: Text HOME to 741741 NAMI Helpline: 1-800-950-NAMI (6264) – Monday-Friday 10am-10pm ET
Disclaimer
This article is for educational purposes only and does not constitute medical advice. Depression treatment should be individualized with a qualified healthcare provider. Do not start, stop, or adjust medications without medical supervision.
References
- Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 21 antidepressant drugs. The Lancet. 2018;391(10128):1357-1366. https://doi.org/10.1016/S0140-6736(17)32802-7
- Cuijpers P, Quero S, Noma H, et al. Psychotherapies for depression: a network meta-analysis. World Psychiatry. 2021;20(2):283-293. https://doi.org/10.1002/wps.20860
- Singh B, Olds T, Curtis R, et al. Effectiveness of physical activity interventions for improving depression. British Medical Journal. 2023;380:e072031. https://doi.org/10.1136/bmj-2022-072031
- Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients (STAR*D). American Journal of Psychiatry. 2006;163(11):1905-1917. https://doi.org/10.1176/ajp.2006.163.11.1905
- Lam RW, Levitt AJ, Levitan RD, et al. Efficacy of bright light treatment, fluoxetine, and the combination in patients with nonseasonal major depressive disorder (CANMAT). JAMA Psychiatry. 2016;73(1):56-63. https://doi.org/10.1001/jamapsychiatry.2015.2235
- Papakostas GI, Ionescu DF. Towards new mechanisms: an update on therapeutics for treatment-resistant major depressive disorder. Molecular Psychiatry. 2015;20(10):1142-1150. https://doi.org/10.1038/mp.2015.92
- Segal ZV, Williams JMG, Teasdale JD. Mindfulness-Based Cognitive Therapy for Depression. 2nd ed. New York: Guilford Press; 2013.
- National Institute of Mental Health (NIMH). Depression. https://www.nimh.nih.gov/health/topics/depression
- American Psychological Association. Depression treatment. https://www.apa.org/depression-guideline
- UK National Institute for Health and Care Excellence (NICE). Depression in adults: treatment and management. 2022. https://www.nice.org.uk/guidance/ng222